LTG-001, a selective inhibitor for treatment of acute pain, was granted Fast Track designation by the Food and Drug Administration (FDA).

Suzetrigine, an oral, highly selective NaV1.8 pain signal inhibitor, showed statistically significant and clinically meaningful reduction in pain on the numeric pain rating scale (NPRS ...

Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch– First ...

We expect the next 12 to 24 months will represent a catalyst-rich period for Xenon as we continue to advance our deep pipeline of promising ...